AIGH Capital Management LLC Sells 2,625,753 Shares of TFF Pharmaceuticals, Inc. (NASDAQ:TFFP)

AIGH Capital Management LLC lessened its stake in shares of TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) by 98.9% during the fourth quarter, Holdings Channel.com reports. The firm owned 29,482 shares of the company’s stock after selling 2,625,753 shares during the period. AIGH Capital Management LLC’s holdings in TFF Pharmaceuticals were worth $207,000 as of its most recent SEC filing.

Separately, Worth Venture Partners LLC boosted its position in shares of TFF Pharmaceuticals by 66.2% during the 3rd quarter. Worth Venture Partners LLC now owns 646,832 shares of the company’s stock worth $226,000 after purchasing an additional 257,722 shares in the last quarter. 15.25% of the stock is currently owned by hedge funds and other institutional investors.

TFF Pharmaceuticals Price Performance

Shares of TFFP stock traded up $0.17 on Monday, reaching $2.21. 29,900 shares of the company were exchanged, compared to its average volume of 33,286. TFF Pharmaceuticals, Inc. has a one year low of $1.54 and a one year high of $15.95. The company has a market cap of $6.85 million, a price-to-earnings ratio of -0.22 and a beta of 1.44. The company has a 50-day moving average of $3.89 and a 200-day moving average of $5.83.

TFF Pharmaceuticals (NASDAQ:TFFP) last posted its earnings results on Thursday, March 28th. The company reported ($2.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.00) by ($0.01). TFF Pharmaceuticals had a negative return on equity of 195.14% and a negative net margin of 2,251.52%. The business had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.20 million. As a group, sell-side analysts predict that TFF Pharmaceuticals, Inc. will post -6.51 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Roth Mkm cut their price objective on shares of TFF Pharmaceuticals from $56.00 to $44.00 and set a “buy” rating on the stock in a research report on Thursday, March 28th.

TFF Pharmaceuticals Company Profile

TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.